NTRK1 and breast cancer: Since the creation and approval of the HER2 antibody trastuzumab for BC treatment in the 1990s, there has been an eruption of HER2- and receptor tyrosine kinase (RTK)-targeted therapeutics that include monoclonal antibodies, antibody–drug conjugates, and receptor tyrosine kinase inhibitors [8,30].